Valence ロゴ
人気
ログイン

ウォッチリストに追加

Fortress Biotech Inc.

NasdaqCM: FBIOP · リアルタイム株価 · USD
18.30
+0.03 (0.16%)
終値時点： Aug 21, 2026, 3:33 PM
18.16
-0.77%
時間外: 4:10 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

Fortress Biotech Inc.（FBIOP）の株価・分析・データ

0.16%
買気配18.1
時価総額n/a
売上高（TTM）68.47M
純利益（TTM）103.37M
1.21
-0.86
n/a
n/a
PBR（TTM）3.71
PSR（TTM）n/a
決算発表日n/a
売気配18.17
出来高9,099
平均出来高（20日）21,511
始値18.30
前日終値18.27
当日レンジ18.30 - 18.59
52週レンジ6.27 - 21.43
アナリストn/a
目標株価n/a
配当n/a
権利落ち日2024年6月14日

FBIOPについて

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical ...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Nov 14, 2017
従業員数 78
上場取引所 NasdaqCM
ティッカー FBIOP
ウェブサイト https://www.fortressbiotech.com
企業情報の全文

業績

2025年のFortress Biotechの売上高は63.26Mで、前年の57.67Mから9.69%の増加でした。 利益は6.82Mで、-114.82%の減少でした。

財務諸表
news image

1週間前 · Moby

Fortress Biotech, Inc. Q2 2026 Earnings Call Summary

Moby summary of Fortress Biotech, Inc.'s Q2 2026 earnings call

news image

1週間前 · Motley Fool

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Emrosi prescriptions jumped 20% sequentially with payer coverage climbing to 38%.

news image

1週間前 · MarketBeat

Fortress Biotech Q2 Earnings Call Highlights

Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Exe...

news image

1か月前 · Simply Wall St.

Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes

Journey Medical is back in focus as analysts revisit their price targets in light of fresh information around its role inside Fortress Biotech and the implied value of its shares and cash position. Re...

news image

5か月前 · TipRanks

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Re...

2ページ中1ページ